US 8,795,975 B2 · Methods and compositions for diagnosis and risk prediction in heart failure

Abstract

The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.

Claims26

Dependent claims

A method of diagnosing heart failure in a subject, comprising:

performing one or more assays selected from the group consisting of an assay that detects WAP four-disulfide core domain protein 2, an assay that detects ESAM, an assay that detects LTBR, an assay that detects Mesothelin, an assay that detects Syndecan-1, an assay that detects TROY, and an assay that detects PIGR on a body fluid sample obtained from said subject, thereby providing one or more assay result(s);
and
assigning a diagnosis that the subject has or does not have heart failure based on the assay result(s) obtained.

A method of assigning one or more of a mortality risk due to cardiovascular disease, a risk of myocardial infarction, a risk of rehospitalization due to heart failure, a risk of stroke, or a risk of a transient ischemic attack to a subject having clinically apparent coronary heart disease, comprising:

performing one or more assays selected from the group consisting of an assay that detects WAP four-disulfide core domain protein 2, an assay that detects ESAM, an assay that detects LTBR, an assay that detects Mesothelin, an assay that detects Syndecan-1, an assay that detects TROY, and an assay that detects PIGR on a body fluid sample obtained from said subject, thereby providing one or more assay result(s);
and
assigning the risk to the subject based on the assay result(s) obtained.

performing one or more assays selected from the group consisting of an assay that detects WAP four-disulfide core domain protein 2, an assay that detects ESAM, an assay that detects LTBR, an assay that detects Mesothelin, an assay that detects Syndecan-1, an assay that detects TROY, and an assay that detects PIGR on a body fluid sample obtained from said subject, thereby providing one or more assay result(s);
and
assigning the risk to the subject based on the assay result(s) obtained.

Dependencies are inferred from the claim text.

Facts

Application

13/990,393Filed 25 Nov 2011 · us provisional application

Priority

29 Nov 2010

Published

US 2014/0147867 A129 May 2014

Granted

5 Aug 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

G01N 33/6893
Involving proteins, peptides or amino acids: related to diseases not provided for elsewhere
G01N 2800/325
Cardiovascular disorders: heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
G01N 2800/60
Detection or diagnosis of diseases: complex ways of combining multiple protein biomarkers for diagnosis
G01N
Investigating or analysing materials by determining their chemical or physical properties

Methods and compositions for diagnosis and risk prediction in heart failure

Life of this patent

Methods and compositions for diagnosis and risk prediction in heart failure

Life of this patent

Abstract

Claims26